14-May-2024
No headlines found.
Ekso Indego Personal to be Featured on 'Health Uncensored' with Dr. Drew Pinsky
Globe Newswire (Fri, 10-May 8:00 AM ET)
Ekso Bionics Announces First Quarter 2024 Financial Results
Globe Newswire (Mon, 29-Apr 4:05 PM ET)
Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024
Globe Newswire (Mon, 22-Apr 8:00 AM ET)
Globe Newswire (Fri, 12-Apr 8:00 AM ET)
Ekso Bionics Reports Record Annual Revenue of $18.3 Million
Globe Newswire (Mon, 4-Mar 4:05 PM ET)
Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Globe Newswire (Mon, 26-Feb 8:00 AM ET)
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.
Ekso Bionics Holdings trades on the NASDAQ stock market under the symbol EKSO.
As of May 14, 2024, EKSO stock price climbed to $1.44 with 71,023 million shares trading.
EKSO has a beta of 1.74, meaning it tends to be more sensitive to market movements. EKSO has a correlation of 0.04 to the broad based SPY ETF.
EKSO has a market cap of $25.78 million. This is considered a Sub-Micro Cap stock.
Last quarter Ekso Bionics Holdings reported $4 million in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.04.
In the last 3 years, EKSO stock traded as high as $6.10 and as low as $.62.
The top ETF exchange traded funds that EKSO belongs to (by Net Assets): VTI, VXF, DFAC.
EKSO has underperformed the market in the last year with a return of -7.7%, while the SPY ETF gained +28.8%. In the last 3 month period, EKSO fell short of the market, returning -30.4%, while SPY returned +5.3%. However, in the most recent 2 weeks EKSO has outperformed the stock market by returning +16.1%, while SPY returned +4.2%.
EKSO support price is $1.29 and resistance is $1.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EKSO stock will trade within this expected range on the day.